Phase I study of erlotinib (tarceva) and temsirolimus (CCI-779) for patients with recurrent malignant gliomas (NABTC 04-02)

被引：0
作者：
Wen, P. Y.
Chang, S. M.
Kuhn, J.
Lamborn, K.
Robins, H. I.
Cloughesy, T.
Gilbert, M. R.
Yung, W. K. A.
Mehta, M.
DeAngelis, L. M.
Abrey, L. E.
Kesari, S.
Drappatz, J.
Lassman, A. B.
Dancey, J.
Prados, M. D.
机构：
[1] N Amer Brain Tumor Consortium, Bethesda, MD USA
[2] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA
来源：
NEURO-ONCOLOGY | 2006年 / 8卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：454 / 454
页数：1
相关论文
共 50 条
  • [21] A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer
    Hidalgo, Manuel
    Buckner, Jan C.
    Erlichman, Charles
    Pollack, Marilyn S.
    Boni, Joseph P.
    Dukart, Gary
    Marshall, Bonnie
    Speicher, Lisa
    Moore, Laurence
    Rowinsky, Eric K.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (19) : 5755 - 5763
  • [22] Phase I Trial of Lenalidomide and CCI-779 in Patients with Relapsed Multiple Myeloma
    Hofmeister, Craig C.
    Benson, Don
    Efebera, Yvonne A.
    Farag, Sherif
    Grever, Michael R.
    [J]. BLOOD, 2009, 114 (22) : 1126 - 1126
  • [23] Phase I and pharmacological study of CCI-779, a cell cycle inhibitor.
    Hidalgo, M
    Rowinsky, E
    Erlichman, C
    Drengler, R
    Marshall, B
    Adjei, A
    Hammond, L
    Galanis, E
    Edwards, T
    Burton, J
    Boni, J
    Tolcher, A
    Dukart, G
    Buckner, J
    [J]. CLINICAL CANCER RESEARCH, 2000, 6 : 4548S - 4549S
  • [24] A Phase II Study of Temsirolimus (CCI-779) in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma.
    Ansell, Stephen M.
    Tang, Hui
    Kurtin, Paul
    Koenig, Patricia
    Inwards, David J.
    Shah, Keith
    Witzig, Thomas E.
    [J]. BLOOD, 2009, 114 (22) : 664 - 665
  • [25] A PHASE I TRIAL OF DASATINIB (SPRYCEL) AND ERLOTINIB (TARCEVA) FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMA
    Reardon, David
    Desjardins, Annick
    Vredenburgh, James
    Friedman, Allan
    Sampson, John
    Gururangan, Sridharan
    Rich, Jeremy
    Friedman, Henry
    [J]. NEURO-ONCOLOGY, 2008, 10 (05) : 840 - 840
  • [26] A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: AChildren's Oncology Group Phase I Consortium Report
    Fouladi, Maryam
    Perentesis, John P.
    Wagner, Lars M.
    Vinks, Alexander A.
    Reid, Joel M.
    Ahern, Charlotte
    Thomas, George
    Mercer, Carol A.
    Krueger, Darcy A.
    Houghton, Peter J.
    Doyle, L. Austin
    Chen, Helen
    Weigel, Brenda
    Blaney, Susan M.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (07) : 1558 - 1565
  • [27] A Phase 2 Study of Temsirolimus (CCI-779) in Patients With Soft Tissue Sarcomas A Study of the Mayo Phase 2 Consortium (P2C)
    Okuno, Scott
    Bailey, Howard
    Mahoney, Michelle R.
    Adkins, Douglas
    Maples, William
    Fitch, Tom
    Ettinger, David
    Erlichman, Charles
    Sarkaria, Jann N.
    [J]. CANCER, 2011, 117 (15) : 3468 - 3475
  • [28] Phase II trial of temsirolimus (CCI-779) in patients with relapsed or refractory multiple myeloma (MM): Preliminary results.
    Farag, S. S.
    Zhang, S.
    Miller, M.
    Buckner, M.
    Kraut, E.
    Chan, K.
    Eng, C.
    Byrd, J. C.
    Dancey, J. E.
    Grever, M. R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 450S - 450S
  • [29] Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
    Chan, S
    Scheulen, ME
    Johnston, S
    Mross, K
    Cardoso, F
    Dittrich, C
    Eiermann, W
    Hess, D
    Morant, R
    Semiglazov, V
    Borner, M
    Salzberg, M
    Ostapenko, V
    Illiger, HJ
    Behringer, D
    Bardy-Bouxin, N
    Boni, J
    Kong, S
    Cincotta, M
    Moore, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5314 - 5322
  • [30] A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b
    Oza, A. M.
    Elit, L.
    Provencher, D.
    Biagi, J. J.
    Panasci, L.
    Sederias, J.
    Dancey, J. E.
    Tsao, S.
    Eisenhauer, E. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345